1. Home
  2. BHRB vs GERN Comparison

BHRB vs GERN Comparison

Compare BHRB & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burke & Herbert Financial Services Corp.

BHRB

Burke & Herbert Financial Services Corp.

HOLD

Current Price

$70.18

Market Cap

968.8M

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.40

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHRB
GERN
Founded
1852
1990
Country
United States
United States
Employees
N/A
258
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
968.8M
808.3M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
BHRB
GERN
Price
$70.18
$1.40
Analyst Decision
Buy
Hold
Analyst Count
5
3
Target Price
$71.80
$2.17
AVG Volume (30 Days)
190.8K
13.7M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
3.46%
N/A
EPS Growth
173.76
N/A
EPS
1.79
N/A
Revenue
N/A
N/A
Revenue This Year
$36.62
$26.91
Revenue Next Year
$10.06
$43.75
P/E Ratio
$39.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$56.35
$1.04
52 Week High
$73.69
$2.01

Technical Indicators

Market Signals
Indicator
BHRB
GERN
Relative Strength Index (RSI) 59.11 52.11
Support Level $61.32 $1.23
Resistance Level $70.71 $1.46
Average True Range (ATR) 1.76 0.09
MACD -0.15 0.01
Stochastic Oscillator 46.46 34.72

Price Performance

Historical Comparison
BHRB
GERN

About BHRB Burke & Herbert Financial Services Corp.

Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: